Publication Name	World Journal of Cardiology
Manuscript ID	73160
Country	Greece

Received	2021-11-11 12:55
Peer-Review Started	2021-11-11 12:57
To Make the First Decision
Return for Revision	2021-12-27 02:50
Revised	2021-12-29 11:00
Second Decision	2022-03-10 05:48
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2022-03-17 04:18
Articles in Press	2022-03-17 04:18
Publication Fee Transferred
Edit the Manuscript by Language Editor	2022-03-08 01:17
Typeset the Manuscript	2022-04-11 09:31
Publish the Manuscript Online	2022-04-19 03:18

ISSN	1949-8462 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Cardiac & Cardiovascular Systems
Manuscript Type	Letter to the Editor
Article Title	Glucose lowering does not necessarily reduce cardiovascular risk in type 2 diabetes
Manuscript Source	Invited Manuscript
All Author List	Angeliki Bourazana, Grigorios Giamouzis, John Skoularigis, Filippos Triposkiadis and Andrew Xanthopoulos
Funding Agency and Grant Number
Corresponding Author	Andrew Xanthopoulos, FACC, MD, PhD, Doctor, Department of Cardiology, University Hospital of Larissa, Mezourlo, Larissa 41110, Greece. andrewvxanth@gmail.com
Key Words	Dipeptidyl peptidase-4 inhibitors; Diabetes mellitus; Outcomes; Meta-analysis; Heart failure; Atrial flutter
Core Tip	Dipeptidyl peptidase-4 inhibitors are a safe and effective glucose lowering treatment option in patients with type 2 diabetes mellitus. However, their effect on cardiovascular outcomes in diabetic patients has been neutral. The potential correlation between atrial flutter and dipeptidyl peptidase-4 inhibitors administration is an interesting finding, but since currently there is no sheer underlying pathophysiologic mechanism to justify it, more evidence is required.
Publish Date	2022-04-19 03:18
Citation	Bourazana A, Giamouzis G, Skoularigis J, Triposkiadis F, Xanthopoulos A. Glucose lowering does not necessarily reduce cardiovascular risk in type 2 diabetes. World J Cardiol 2022; 14(4): 266-270
URL	https://www.wjgnet.com/1949-8462/full/v14/i4/266.htm
DOI	https://dx.doi.org/10.4330/wjc.v14.i4.266

Full Article (PDF)	WJC-14-266.pdf
Full Article (Word)	WJC-14-266.docx
Manuscript File	73160_Auto_Edited-YJM-FilipodiaCL.docx
Answering Reviewers	73160-Answering reviewers.pdf
Audio Core Tip	73160-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	73160-Conflict-of-interest statement.pdf
Copyright License Agreement	73160-Copyright license agreement.pdf
Peer-review Report	73160-Peer-review(s).pdf
Scientific Editor Work List	73160-Scientific editor work list.pdf